New York, May 21, 2026, 10:05 EDT
- PROCEPT BioRobotics shares added 0.6% to $28.29 early, with the stock moving between $28.07 and $28.29 so far in the session, according to latest data.
- Nasdaq was trading during regular hours. The exchange’s next listed U.S. holiday closure is Memorial Day on May 25, 2026.
- Investors are looking at better clinical data for Aquablation but also factoring in PROCEPT’s losses and risk around execution.
PROCEPT BioRobotics shares were slightly higher early Thursday, up 18 cents to $28.29. The stock was steadier than much of the medical-device group as Wall Street opened lower again with new jitters over oil and the Middle East. According to Reuters, the Dow, S&P 500 and Nasdaq all slipped at the open.
Procept BioRobotics shares barely moved, but even a slight gain is notable for a stock still working to regain trust after a rough guidance cut earlier this year. The company, which most recently was valued around $1.60 billion, has to prove adoption of its Aquablation systems can fuel more consistent procedures, boost consumable sales, and slow its cash burn.
PROCEPT isn’t moving off a fresh earnings print. Its latest press release, out May 14, said the American Urological Association raised support for Aquablation therapy, its robot-assisted waterjet treatment for men with lower urinary tract symptoms from BPH, or enlarged prostate. The guideline update now includes prostates sized 30–80 mL, and recognizes use in large prostates from 80–150 mL.
Chief Executive Larry Wood said the change in guideline comes as “growing adoption” continues. Houston Methodist’s Ricardo Gonzalez, MD, said the updated guidance tells clinicians to “offer Aquablation therapy.” PROCEPT BioRobotics Corp
PROCEPT’s next hurdle is whether support translates into the numbers. First-quarter revenue came in at $83.1 million, 20% higher than a year ago. The company said about 12,200 U.S. procedures were done, which is up around 30%. PROCEPT sold 49 Hydros systems in the U.S., counting two replacements, and kept its 2026 revenue outlook at $390 million to $410 million.
Wood said first-quarter revenue got a boost from “strong U.S. system sales and improved pricing,” but warned of “near-term disruption” tied to a commercial realignment. Net loss came in at $31.6 million, wider than the $24.7 million loss a year ago. Adjusted EBITDA loss was $18.1 million. Adjusted EBITDA strips out interest, taxes, depreciation, amortization and some items like stock-based compensation. PROCEPT BioRobotics Corp
Medical device stocks were mostly lower. The iShares U.S. Medical Devices ETF lost 1.7%. Intuitive Surgical fell 2.6%. Boston Scientific was down 0.2% in early trading. That left PRCT’s small gain going the other way from most bigger device companies.
PROCEPT isn’t going after Intuitive’s full platform for surgical robots. The company is focusing on convincing hospitals and urologists to standardize a robotic treatment for BPH. The strategy is to build recurring revenue from BPH procedures and device handpieces.
Execution remains a concern. First-quarter handpiece sales tracked at about 95% of U.S. procedures, and the company is still guiding for full-year U.S. procedure growth of 39% to 48%. But if hospital capital spending drops, if sales-force adjustments take longer than expected, or if handpiece sales lag procedures, the outlook could get tougher to hit.
The concern has been around before. When the company posted its fourth-quarter results, Investor’s Business Daily cited Leerink Partners analyst Mike Kratky, who called the numbers “especially disappointing.” Kratky trimmed his price target to $30 from $55, though he kept his outperform rating. Investors
PROCEPT BioRobotics Corp’s next management appearance is set for the William Blair Growth Stock Conference on June 2, then the Truist Med-Tech Conference on June 16. For PRCT, it’s not just about the slides — it’s whether management can keep investors looking at procedure growth instead of the previous quarter’s disruption.
